Please ensure Javascript is enabled for purposes of website accessibility

Why Amarin Stock Is on the Mend Today

By George Budwell - Apr 8, 2020 at 11:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Amarin's shares continue to rebound after last month's steep drop.

What happened

Shares of the Irish biopharma Amarin Corp. (AMRN 0.78%) rose by as much as 11.9% in early action Wednesday morning. While the company didn't release any news that would spark this double-digit rally today, Amarin's shares have been gaining favor among a number of Wall Street analysts and bargain hunters ever since the company's cliff dive at the end of March.

In fact, Amarin's stock is up by almost 40% since hitting a multiyear low at the end of March. The biopharma's shares have cooled off a bit since their red-hot start to Wednesday's trading session, but they're still up by a healthy 10.3% on higher-than-normal volume, as of 11:41 a.m. EDT. 

A hand using a red string to illustrate a positive growth trend.

Image Source: Getty Images.

So what

As a refresher, Amarin's shares lost over 70% of their value on March 31 in response to an adverse patent ruling for Vascepa in the United States. This patent ruling is a big deal because it potentially paves the way for generic competitors to enter the U.S. market.

Even under a worst-case scenario, though, a generic competitor probably won't enter the U.S. market for at least a full year from now. Amarin, after all, plans on appealing this unfavorable legal decision, a process that's expected to take no less than 12 months.  

Now what

The good news is that Amarin should hear back about Vascepa's pending European regulatory filing by the end of the year. Some analysts think an approval in the EU could be worth $1.5 billion to $2 billion in annual sales, which is a sizable commercial opportunity for a company with a market cap of about $2 billion right now.

All in all, this beaten-down biopharma stock arguably still has a lot to offer growth and value investors alike, even with this seminal patent issue hanging in the balance. 

George Budwell owns shares of Amarin. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
AMRN
$1.29 (0.78%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.